#USA #Barcelona #SuanNutra #prebiotics #Myota

SUANNUTRA and Myota Form Strategic Alliance

In a significant development in the realm of nutraceuticals, SUANNUTRA, known for its excellence in nutraceutical ingredients, has forged an exclusive partnership with Myota, a prominent UK-based company. This collaboration aims to deliver high-quality prebiotic solutions, specifically designed to enhance metabolic health across key markets, including the US, UK, and EU. Their flagship product, the Metabolic Regulator, signifies a breakthrough in the field of gut health and overall wellness.

The Power of Precision Prebiotics

The essence of this partnership lies in its scientific foundation. At the core of the collaboration is Myota’s unique blend of nine plant-based fibers that facilitate the production of beneficial short-chain fatty acids (SCFAs). This is achieved through targeted fermentation by gut microbiota, positioning it as a pioneering approach to gut health. SUANNUTRA’s flagship ingredient, Metabolaid, complements this process by modulating the microbiome, indirectly aiding the production of SCFAs. Together, these innovations present a multi-faceted approach to metabolic health, optimizing prebiotic action within the gut and nurturing systemic balance.

Research studies, including those conducted at MIT and various third-party clinical trials, have demonstrated the effectiveness of the Metabolic Regulator in supporting healthy blood sugar levels and maintaining cholesterol within normal ranges. Moreover, it also aids in minimizing post-meal glucose spikes, making it an ideal solution for those conscious of their metabolic health. Importantly, its low-FODMAP formulation ensures its suitability for individuals with digestive sensitivities.

Voices from the Leaders

Anthony Weston, the CEO of SUANNUTRA, expressed enthusiasm about the partnership, noting, "This collaboration enriches our product portfolio by incorporating microbiome-friendly solutions, offering advanced support for cardiometabolic wellness. By merging Metabolaid’s enhancement of crucial metabolic pathways with Myota’s prebiotic strategy, we are meeting the emergent health needs in today’s marketplace."

Similarly, Myota's CEO, Dr. Thomas Gurry, shared insights into their innovative approach. He stated, "Pairing our fermentation-optimized prebiotics with SUANNUTRA's clinically validated actives creates significant value. Our goal is to transform the landscape of gut health from a generic approach to a precision-based, systemic wellness paradigm."

Both companies are set to unveil their complete product range at Vitafoods Europe 2025, scheduled for May 20-22, at booth #3K22. This launch will feature custom blends and formulation support, further solidifying their place in the nutraceutical market.

About SUANNUTRA

SUANNUTRA has established itself as a global leader in the nutraceutical field, boasting a portfolio enriched by over 22 clinical studies and six prestigious awards. The company is committed to leveraging groundbreaking science for its products, targeting sectors such as weight management, women's health, and beauty from within.

About Myota

Founded in 2019, Myota has harnessed nearly a decade of research from MIT to develop clean-label, low-FODMAP prebiotic blends. Their focus on customizing fiber blends based on individual microbiome profiles ensures optimal fermentation efficacy and clinical outcomes, thus linking gut health to metabolic wellness.

This groundbreaking partnership between SUANNUTRA and Myota signifies a notable advance in the world of prebiotics, aiming to fulfill the ever-increasing demand for scientifically backed health solutions. As health consciousness continues to rise globally, the offerings from these two innovative companies are positioned to meet the diverse needs of consumers everywhere.